News Future uncertain for Innate and BMS' troubled lirilumab Doubts over future of cancer immunotherapy
News Merck & Co pulls Keytruda lung cancer filing in Europe Blow for Merck as Keytruda sales top $1 billion per quarter.
News BMS files Opdivo in post-surgery setting Opdivo performed better than BMS' Yervoy in clinical trial.
News BMS scores an early victory in the new cancer biomarker batt... Bristol-Myers Squibb is hoping to drive forward its Opdivo cancer immunotherapy franchise by finding a better biomarker than PD-L1 - and has just produced encouraging results in a trial loo
News NICE okays CDF funding for BMS' Opdivo in head and neck canc... Cancer Drugs Fund will reimburse Opdivo for 2 years
News Bayer left playing catch-up with BMS after Xarelto failure BMS' rival anticoagulant takes commanding market lead.
News GBL joins CVC in €10.7bn takeover bid for Recordati A consortium of investors has made a €10.7bn offer to take Italian pharma Recordati private, but some analysts are sceptical the deal will go through.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
